Genprex receives Nasdaq deficiency notice for bid price below $1.00; 180-day cure period

Genprex, Inc.

Nasdaq letter dated Sept 26, 2024; stock fails minimum $1.00 bid price for 30 consecutive business days.
Cure period ends March 25, 2025; must have $1.00 closing bid for 10 consecutive days to regain compliance.
Company may qualify for additional 180-day period if it meets other listing standards and notifies Nasdaq.
Potential actions include reverse stock split; delisting risk if unable to cure.
Common stock continues trading on Nasdaq Capital Market while Company monitors bid price.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.